Data may prove too little too late for the antibody drug conjugate, as GSK takes a cautious stance over future commercial viability.
Newly unveiled Phase III data could help GSK bring its multiple myeloma therapy Blenrep back to the market but it will await a further positive readout before making a decision.
GSK’s antibody drug conjugate Blenrep (belantamab mafodotin) was removed from the US market in late 2022 when it failed to...
The biopharma sector booked nearly the same number of acquisitions in each of the past two quarters, according to Evaluate data, but there are some encouraging signs in Q2.
Teva VP-global R&D and chief medical officer Eric Hughes talked to Scrip about building the company’s innovative pipeline in its growth-acceleration phase.
Rumor mill suggests a $15bn licensing deal for ivonescimab is in the offing.
Emerging Company Profile: Early-stage biotech Eolo will seek cash and deals for its novel obesity drug SANA after positive Phase I results for weight loss, lean muscle mass preservation and fat mass reduction.
Psychedelics appear to be in vogue after years of being relegated to alternative medicine. But investor pushback after the highly anticipated release of Phase III trial data by Compass Pathways reveals an increasingly high bar for development.
Emerging Company Profile: Early-stage biotech Eolo will seek cash and deals for its novel obesity drug SANA after positive Phase I results for weight loss, lean muscle mass preservation and fat mass reduction.
Roctavian shows durable bleed control and safety over five years, but high costs and access hurdles limit its commercial outlook.
